These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28901922)

  • 1. CAR T-cells: an exciting frontier in cancer therapy.
    The Lancet
    Lancet; 2017 Sep; 390(10099):1006. PubMed ID: 28901922
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineered cell therapy for cancer gets thumbs up from FDA advisers.
    Ledford H
    Nature; 2017 Jul; 547(7663):270. PubMed ID: 28726836
    [No Abstract]   [Full Text] [Related]  

  • 3. Universal CAR T Cells Treat Leukemia.
    Cancer Discov; 2017 Apr; 7(4):342. PubMed ID: 28193774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T cells: driving the road from the laboratory to the clinic.
    Cheadle EJ; Gornall H; Baldan V; Hanson V; Hawkins RE; Gilham DE
    Immunol Rev; 2014 Jan; 257(1):91-106. PubMed ID: 24329792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy.
    Tessema FA; Darrow JJ
    J Law Med Ethics; 2017 Dec; 45(4):692-697. PubMed ID: 30027797
    [No Abstract]   [Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular Immunotherapy in B-Cell Malignancy.
    Schwarzbich MA; Witzens-Harig M
    Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracing the Path of CAR T Cells.
    Cancer Discov; 2017 Apr; 7(4):OF5. PubMed ID: 28193777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The CAR-T cells are here].
    Croizier C; Douge A; Bay JO; Lemal R
    Bull Cancer; 2018 Sep; 105(9):743-745. PubMed ID: 30119830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
    Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
    Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
    Porter DL
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
    [No Abstract]   [Full Text] [Related]  

  • 15. Building blocks for institutional preparation of CTL019 delivery.
    McGuirk J; Waller EK; Qayed M; Abhyankar S; Ericson S; Holman P; Keir C; Myers GD
    Cytotherapy; 2017 Sep; 19(9):1015-1024. PubMed ID: 28754600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobody Based Dual Specific CARs.
    De Munter S; Ingels J; Goetgeluk G; Bonte S; Pille M; Weening K; Kerre T; Abken H; Vandekerckhove B
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.
    Han C; Sim SJ; Kim SH; Singh R; Hwang S; Kim YI; Park SH; Kim KH; Lee DG; Oh HS; Lee S; Kim YH; Choi BK; Kwon BS
    Nat Commun; 2018 Feb; 9(1):468. PubMed ID: 29391449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
    Oh I; Oh Y; Ohmine K
    Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD22 CAR Therapy Leads to ALL Remissions.
    Cancer Discov; 2017 Feb; 7(2):120. PubMed ID: 28069570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.